Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869
To estimate the effect of food on the oral bioavailability and effect of diurnal variation on the pharmacokinetics of ABT-869.
Advanced Solid Tumors
DRUG: ABT-869
Pharmacokinetic, Blood samples for the pharmacokinetics of linifanib will be collected for each subject and each regimen (fasting, fed, AM and PM dosings)., Various timepoints|ECG Evaluation, Triplicate ECG will be performed at designated timepoints., Various timepoints|Adverse Events, Only treatment emergent AEs will be included. Toxicity grade, relationship to study drug and AEs leading to discontinuation will be evaluated., Throught the study|Lab data and vital signs, Blood chemistry and hematology will be analyzed based on the regimen and dosing and overall. 24 hr ABPM will be analyzed by regimen and dosing time and overall., Various timepoints
This study is a pharmacokinetic study designed to evaluate the effect of food on the oral bioavailability and effect of diurnal variation on the pharmacokinetics of ABT-869. Triplicate ECG performed to determine the effect of ABT-869 on QT prolongation . Subjects may continue receiving linifanib after completion of the study.